Search clinical trials for: JNJ-61393215

Total 1086 results

Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers

Neoplasms

United Kingdom, Spain, United States, Russian Federation, Poland, Sweden, Moldova, Republic of
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

Advanced Solid Tumor

France, United States, Japan, Belgium, United Kingdom, Germany, Korea, Republic of, Poland, Taiwan, China, Italy, Spain, Australia, Brazil, Argentina
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)

Hematological Malignancies

Canada, United States, France, Italy, United Kingdom, Germany, Belgium, Netherlands, Spain, Sweden, China
Herbert Meltzer
Janssen Research & Development, LLC

Completed

Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients

Bipolar Disorder

United States
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Different Dose Levels of Ad26.COV2.S in Healthy Adolescents From 12 to 17 Years Inclusive (HORIZON 2)

Coronavirus Disease-2019 (COVID-19) Prevention

South Africa, Brazil, Argentina, Mexico, India
Janssen Research & Development, LLC

Withdrawn

A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies

Heart Failure
Janssen Research & Development, LLC

Completed

The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study of the Histone-deacetylase Inhibitor JNJ-26481585 in Patients With Advanced or Refractory Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Advanced or Refractory Leukemia

United States
Johnson & Johnson Pharmaceutical Research & Development...
Janssen Pharmaceutica N.V., Belgium

Completed

A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.

Pharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
Janssen Research & Development, LLC

Completed

Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants

Alzheimer Disease

United States
King's College London

Recruiting

Imaging 5HT7 Antagonist Effects in Bipolar Disorder

Bipolar Disorder

United Kingdom
Janssen Research & Development, LLC

Active, not recruiting

A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

China
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Hematologic Malignancies

Japan
Janssen Sciences Ireland UC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-73763989

Hepatic Impairment

Germany
Janssen Scientific Affairs, LLC

Approved for marketing

Expanded Access Program (EAP) for Participants With Advanced Cancers and Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations Who Have Exhausted All Treatment Options

Advanced Cancers and FGFR Genetic Alterations
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis

Psoriasis

United States, Poland
Janssen Research & Development, LLC

Terminated

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) (DAISY)

Respiratory Tract Infections

Belgium, Czechia, Taiwan, Japan, Hungary, Thailand, United States, Germany, Korea, Republic of, Turkey, China, Spain, Brazil, Bulgaria, Malaysia, Estonia, Argentina, Poland, Israel, Italy, Latvia, Mexico, Panama, Slovakia, Sweden, Ukraine
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Neoplasm

Japan
OHSU Knight Cancer Institute
Oregon Health and Science University; Janssen, LP; The Leukemia and Lymphoma...

Terminated

JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease (Autonomy)

Cognitive Dysfunction | Dementia | Alzheimer Disease

United States, Belgium, France, Japan, United Kingdom, Spain, Canada, Australia, Sweden, Netherlands
Aragon Pharmaceuticals, Inc.

No longer available

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms

Colombia, Brazil, Mexico
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate Dose Levels of Ad26.COV2.S Administered as a Two-dose Schedule in Healthy Adults

COVID-19 Prevention

United States, Germany, Brazil, Poland, South Africa
Janssen Research & Development, LLC

Completed

A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

Advanced Solid Neoplasms

Spain, Israel
Janssen Pharmaceutical K.K.

Completed

A Study of Ad26.COV2.S in Adults (COVID-19)

Healthy

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants

Healthy

Belgium
Janssen Vaccines & Prevention B.V.

Completed

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants

Healthy

Belgium
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy

Prostate Adenocarcinoma | Stage IIB Prostate Cancer AJCC v8

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

Hepatitis B, Chronic

France, Taiwan, Canada, United States, Germany, Spain, Japan, Russian Federation, Turkey, United Kingdom
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Obesity

United States, Belgium, United Kingdom, Sweden, Poland, Canada
M.D. Anderson Cancer Center

Active, not recruiting

Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma | Castration-Resistant...

United States
Janssen Research & Development, LLC

Withdrawn

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5)

Relapsed/ Refractory Multiple Myeloma

United States, Poland
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Withdrawn

A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women

Healthy | Pharmacokinetics | Drug Interactions
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

Pain | Mononeuropathies | Neuralgia | Neuralgia, Postherpetic

United States, Spain, Belgium, Netherlands
Janssen Research & Development, LLC

Active, not recruiting

A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

Lymphoma, Non-Hodgkin | Leukemia, Lymphocytic, Chronic, B-Cell

Denmark, France, Poland, Sweden
Janssen Research & Development, LLC

Terminated

A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection

Hepatitis B, Chronic

France, Germany, Spain, Poland, Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function

Kidney Failure, Chronic

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation

Healthy

Belgium
Janssen Research & Development, LLC

Completed

Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

Alzheimer Disease

France, Belgium, Germany, Spain, Sweden
Janssen Pharmaceutical K.K.

Completed

Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

Prostatic Neoplasms

Japan
Janssen Research & Development, LLC

Completed

A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury

Traumatic Brain Injury

France, Belgium

3

Subscribe